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Background: Rotavirus is one of the major causes of severe gastroenteritis in 
infants and young children worldwide.
Methods: We retrospectively analyzed the demographic and clinical profiles of 
rotavirus infection among children hospitalized in the Cathay General Hospital, 
Taiwan from May 2004 to April 2007. Children under 15 years of age with gastroen-
teritis were enrolled in the study and had stool specimens tested for the presence 
of rotavirus.
Results: There were 238 participating patients, most of whom were aged 3−5 years 
(44%). The most common symptom was diarrhea (98.7%), and the peak month was 
May (20.4%). All patients were discharged alive with no complications.
Conclusion: Gastroenteritis due to rotavirus infection was found in older children 
between 6 and 12 years of age, as well as in hospitalized children between 3 and 5 
years of age. Most cases occurred in the spring.
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1.  Introduction
Rotavirus infection is one of the most common causes 
of severe gastroenteritis in infants and young chil-
dren in both developed and developing countries. 
In developing countries, rotavirus gastroenteritis is 
responsible for approximately half a million deaths 
per year of children aged under 5 years.1 Little in-
formation on the disease burden and epidemio-
logical profile of rotavirus infection in Taiwan is 
available to help decide whether or not to intro-
duce a rotavirus vaccine. The aim of this study was 
to collect and examine the available epidemiologic 
and clinical data on rotavirus infection at a hospi-
tal in Taiwan.
2.  Materials and Methods
We retrospectively analyzed the age, sex, clinical 
symptoms and signs, laboratory findings, compli-
cations, coexisting diseases, and hospital courses 
of children with rotavirus infection hospitalized at 
Cathay General Hospital from May 2004 to April 
2007. A total of 279 children under 15 years old who 
were hospitalized for gastroenteritis were enrolled 
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in the study. Their stool specimens were tested for 
the presence of rotavirus antigens using the Rapid 
Immunochromatographic Test (Veda Laboratory, 
France). Gastroenteritis was defined as the occur-
rence of diarrhea, including the passage of more 
than three liquid or semi-liquid stools and a clini-
cal history, with or without vomiting.
We excluded patients who had any of the fol-
lowing: (1) had received rotavirus vaccine; (2) had 
coexisting salmonellosis (n = 5); (3) had coexisting 
diseases such as acute otitis media, urinary tract 
infection, respiratory tract infection, or herpangina 
(n = 36). The discharge criteria included (1) no vom-
iting, (2) improvement of diarrhea symptom to the 
passage of fewer than two liquid or semi-liquid 
stools, (3) no fever, and (4) improvements in appe-
tite and activity.
Clinical symptoms and laboratory data were used 
to identify severe gastroenteritis. Admission days, 
seasons, and patient’s age were used to determine 
the incidence of gastroenteritis at different times. 
The spring season was from March to May, summer 
was from June to August, autumn from September to 
November, and winter from December to February. 
The admission dates of patients with different clin-
ical symptoms and laboratory data were assessed 
using t tests. All analyses were conducted using SAS 
version 9.0 (SAS Institute, Cary, NC, USA).
3.  Results
The male to female ratio of the 238 patients in this 
3-year study was 1.3. The mean age was 3.2 ± 2.1 
years. The study patients were divided by age into 
less than 2 years (43%), 3−5 years (44%), 6−8 years 
(10%), and 9−12 years of age (3%; Table 1). The most 
common symptom of rotavirus gastroenteritis was 
diarrhea (98.7%; Table 2). Of the 238 patients, 95 
patients (39.9%) had leukocytosis (white blood 
count > 10 × 109/L); 128 patients (53.8%) had a left 
shift (segments > 74%); 112 patients (46.7%) had 
elevated C-reactive protein level (> 4.8 nmol/L). 
More than half of all patients experienced their ill-
ness in spring, including May (20.4%), April (17.2%) 
and March (14.2%), followed by summer (17.2%), 
winter (16.2%) and fall (14.2%; Table 1). The most 
common length of hospital stay was 4 days (38.2%), 
followed by 5 days (27.5%). The shortest hospital 
stay was 2 days (1.3%) and the longest was 11 days 
(0.4%; Table 1). The most frequently identified 
bacteria in specimens were non-enteropathogenic 
Escherichia coli (194 specimens, 81.5%), followed 
by non-enteropathogenic Klebsiella pneumoniae 
(22 specimens, 9.2%), non-enteropathogenic Entero-
coccus species (18 specimens, 7.5%), and other non-
enteropathogenic pathogens (4 specimens, 1.6%). 
All 238 study patients were discharged alive with 
no complications, and none were rehospitalized. 
No lactose intolerance was found in any patient.
Table 2  Clinical symptoms and laboratory data of pa-
tients with rotavirus gastroenteritis (N = 238)
Symptoms n (%)
Vomiting 220 (92.4)
Diarrhea 235 (98.7)
Poor appetite & activity 230 (96.6)
Abdominal pain 75 (31.3)
Fever 171 (71.8)
Bloody stool 8 (3.4)
Seizure 3 (1.3)
Table 1 Clinical month, admission days and age of patients with rotavirus gastroenteritis
 Clinical month Admission days Patient age
Month Frequency n (%) Hospitalization (d) Frequency n (%) Age (yr) Frequency n (%)
Jan 12 (5.0)  1 0 (0)  ≤ 1 41 (17.2)
Feb 19 (7.9)  2 3 (1.3)  2 61 (25.4)
Mar 34 (14.2)  3 48 (20)  3 50 (21.0)
Apr 41 (17.2)  4 91 (38.2)  4 33 (13.8)
May 49 (20.4)  5 66 (27.5)  5 23 (9.6)
Jun 16 (6.7)  6 19 (7.9)  6 14 (5.8)
Jul 10 (4.2)  7 5 (27.5)  7 4 (1.7)
Aug 15 (6.3)  8 4 (1.7)  8 5 (2.1)
Sep 11 (4.6)  9 1 (0.4)  9 2 (0.8)
Oct 8 (3.3) 10 0 (0) 10 4 (1.7)
Nov 15 (6.3) 11 1 (0.4) 11 0 (0)
Dec 8 (3.3) 12 0 (0) 12 1 (0.4)
Total 238 (100) Total 238 (100) Total 238 (100)
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4.  Discussion
In this study, rotavirus gastroenteritis was charac-
terized by vomiting, diarrhea, fever, abdominal pain, 
poor appetite, and poor activity. Diarrhea was par-
ticularly prominent, but vomiting was usually the 
first sign. This was in agreement with the results of 
other studies.2−4 Rotavirus infections are the lead-
ing cause of severe acute gastroenteritis among 
infants and young children, accounting for an esti-
mated 527,000 deaths worldwide in 2004 among 
children aged under 5 years, mainly in low-income 
countries.5,6 Rotavirus causes few deaths (20−60 
cases) in the United States each year, but remains 
a substantial cause of morbidity among children, 
resulting in approximately 55,000−70,000 hospitali-
zations, 205,000−272,000 emergency department 
visits, and 410,000 physician office visits.4 In the 
European Union, the annual burden of rotavirus dis-
ease is estimated at more than 200 deaths, over 
87,000 admissions, and almost 700,000 outpatient 
visits in children younger than 5 years old.7
Rotaviruses are 70-nm non-enveloped RNA vi-
ruses belonging to the family Reoviridae. The out-
ermost layer contains two structural viral proteins 
(VP): VP4, the protease-cleaved protein (P protein), 
and VP7, the glycoprotein (G protein).8 These two 
proteins define the serotype of the virus and are 
considered critical to vaccine development, since 
they provide targets for neutralizing antibodies that 
might be important for protection.9 Many different 
variants have been described, but most strains in 
Europe, Asia and the United States belong to the 
genotype P[4]G2 or combinations of P[8] with G1, 
3 or 4.10 According to a recent report by Wu et al,3 
the prevalence of serotypes of rotavirus infection 
in Taiwan between 2004 and 2006 was group A VP7 
G (2004, 2005, 2006): G1 (11.9%, 23.4%, 34.4%), 
G2 (35.9%, 17.6%, 6.3%), G3 (26.1%, 19.1%, 34.4%), 
G4 (0, 0.68%, 0), G9 (26.1%, 21.7%, 24.6%), respec-
tively.3 Current vaccines include an oral live at-
tenuated human rotavirus vaccine derived from 
the most common circulating strain G1P[8], which 
has been developed by GlaxoSmithKline, while the 
Merck vaccine is composed of five bovine-human 
reassortants intended to induce serotype-specific 
protection against the four main G types (G1−G4), 
plus the common P[8] antigens.11 Both vaccines are 
used in Taiwan, where they have efficacy against 
G1, G2, G3, G4 and G9 strains.2,4,7
Rotavirus-related hospital admissions occur all 
year round, but rates vary by month.12−16 Spring was 
the peak season for rotavirus gastroenteritis in our 
study. However, outbreaks reported in other devel-
oped countries occurred during the winter.12−16 It is 
possible that the location and temperate climate 
of Taiwan at a latitude of 21−25ºN is associated 
with a year-round pattern of disease that is more 
similar to that found in a developing country than 
an industrialized one.17,18 Most children with rota-
virus gastroenteritis in our study were between the 
ages of 3 and 5 years (44%), which also contrasted 
with the situation in many developed countries, 
where about 60% of hospitalizations due to this in-
fection were among children under 2 years old.19−21 
This suggests that rotavirus could remain an im-
portant pathogen of gastroenteritis in 3−5-year-old 
children in our study.
According to a recent report by Chen et al,22 
the annual social and hospital costs of rotavirus-
associated hospital admissions in Taiwan represented 
about 40% of the monthly salary of an unskilled or 
service worker, and 5.9% of the gross national in-
come. In this study, the total annual social and hospi-
tal costs for rotavirus-hospital admission was around 
US$ 5947, and on average, families spent at least 
US$ 66 when their child’s admission was associated 
with rotavirus infection (data not shown). Current 
vaccines might have the potential to reduce not 
only the morbidity and mortality, but also the health 
care costs associated with rotavirus infection.4
Rotaviruses invade and replicate in the differ-
entiated absorptive columnar cells of the small in-
testinal epithelium. The result is partial disruption 
of the intestinal mucosa, with loss of microvilli and 
a decrease in the villus/crypt ratio.23 The secre-
tory crypt cells proliferate extensively to compen-
sate, leading to substantial fluid and electrolyte 
secretion into the gut. The damage also leads to 
reduced expression of certain digestive enzymes.24 
Lactase is usually the first affected disaccharidase, 
presumably because of its distal location on the 
villus. The immature epithelial cells that replace 
the disrupted mucosa are often lactase deficient, 
leading to secondary lactose deficiency and lactose 
malabsorption.25 However, these symptoms were 
not found in our study.
There are several limitation to the current study. 
First, the results only provided demographic data for 
hospitalized patients and did not include patients 
who visited the out-patient and emergency depart-
ments. Second, the rotavirus grouping was not ge-
notyped, and could therefore not identify any new 
or unusual strains. These limitations could be re-
assessed in future surveillance studies.
The results of this study provide baseline esti-
mates of the current burden and epidemiological 
profile of rotavirus infection in CGH. Gastroenteritis 
due to rotavirus infection was found not only in 
children under 5 years old, but also in older children 
aged between 6 and 12 years. Rotavirus-related 
hospital admissions occurred year-round, but there 
was month-to-month variability in rates, which were 
especially high during the spring.
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